Back to Search
Start Over
The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?
- Source :
-
Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2020 Sep; Vol. 508, pp. 122-129. Date of Electronic Publication: 2020 May 14. - Publication Year :
- 2020
-
Abstract
- Background: The underlying changes of peripheral blood inflammatory cells (PBICs) in COVID-19 patients are little known. Moreover, the risk factors for the underlying changes of PBICs and their predicting role in severe COVID-19 patients remain uncertain.<br />Material and Methods: This retrospective study including two cohorts: the main cohort enrolling 45 patients of severe type serving as study group, and the secondary cohort enrolling 12 patients of no-severe type serving as control group. The PBICs analysis was based on blood routine and lymphocyte subsets. The inflammatory cell levels were compared among patients according to clinical classifications, disease-associated phases, as well as one-month outcomes.<br />Results: Compared with patients of non-severe type, the patients of severe type suffered from significantly decreased counts of lymphocytes, eosinophils, basophils, but increased counts of neutrophils. These PBICs alterations got improved in recovery phase, but persisted or got worse in aggravated phase. Compared with patients in discharged group, the patients in un-discharged/died group suffered from decreased counts of total T lymphocytes, CD4 + T lymphocytes, CD8 + T lymphocytes, as well as NK cells at 2 weeks after treatment. Clinical classification-critically severe was the independently risk factor for lymphopenia (OR = 7.701, 95%CI:1.265-46.893, P = 0.027), eosinopenia (OR = 5.595, 95%CI:1.008-31.054, P = 0.049), and worse one-month outcome (OR = 8.984; 95%CI:1.021-79.061, P = 0.048).<br />Conclusion: Lymphopenia and eosinopenia may serve as predictors of disease severity and disease progression in COVID-19 patients, and enhancing the cellular immunity may contribute to COVID-19 treatment. Thus, PBICs might become a sentinel of COVID-19, and it deserves attention during COVID-19 treatment.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Subjects :
- Aged
Biomarkers blood
COVID-19
Cell Count
Coronavirus Infections blood
Coronavirus Infections physiopathology
Coronavirus Infections virology
Disease Progression
Eosinophils virology
Female
Humans
Killer Cells, Natural pathology
Killer Cells, Natural virology
Lymphocyte Subsets virology
Lymphopenia blood
Lymphopenia physiopathology
Lymphopenia virology
Male
Middle Aged
Monocytes pathology
Monocytes virology
Neutrophils pathology
Neutrophils virology
Pandemics
Pneumonia, Viral blood
Pneumonia, Viral physiopathology
Pneumonia, Viral virology
Prognosis
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Survival Analysis
Betacoronavirus pathogenicity
Coronavirus Infections diagnosis
Eosinophils pathology
Lymphocyte Subsets pathology
Lymphopenia diagnosis
Pneumonia, Viral diagnosis
Subjects
Details
- Language :
- English
- ISSN :
- 1873-3492
- Volume :
- 508
- Database :
- MEDLINE
- Journal :
- Clinica chimica acta; international journal of clinical chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 32417210
- Full Text :
- https://doi.org/10.1016/j.cca.2020.05.027